A deep learning-derived sarcopenia marker, the muscle-bone ratio (MBR), has been shown to predict the efficacy of anti-EGFR maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, potentially identifying those who truly benefit from treatment intensification.